Integra Lifesciences Holdings (IART) Free Cash Flow (2009 - 2026)

Integra Lifesciences Holdings has disclosed Free Cash Flow across 18 years of filings, most recently posting $10.5 million for Q2 2026.

• In Q2 2026, Free Cash Flow rose 193.48% year-over-year to $10.5 million; the TTM figure through Jun 2026 stood at $25.8 million (up 168.94% YoY), while the FY2025 annual figure was -$31.1 million, down 224.39% from the prior year.
• Free Cash Flow came in at $10.5 million for Q2 2026 at Integra Lifesciences Holdings, up from -$5.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $70.9 million in Q4 2022 to a low of -$40.2 million in Q1 2025.
• Average Free Cash Flow over 5 years is $16.4 million, with a median of $12.6 million recorded in 2023.
• The largest YoY upside for Free Cash Flow was 459.59% in 2025 against a maximum downside of 13906.53% in 2025.
• Over 5 years, Free Cash Flow stood at $70.9 million in 2022, then tumbled by 51.73% to $34.2 million in 2023, then sank by 38.21% to $21.1 million in 2024, then tumbled by 125.53% to -$5.4 million in 2025, then surged by 294.42% to $10.5 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were $10.5 million in Q2 2026, -$5.0 million in Q1 2026, and -$5.4 million in Q4 2025.